| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2019-03-08 |
| タイトル |
|
|
タイトル |
Contrast media enhancement reduction predicts tumor response to presurgical molecular-targeting therapy in patients with advanced renal cell carcinoma |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Hosogoe, Shogo
Hatakeyama, Shingo
Kusaka, Ayumu
Hamano, Itsuto
Tanaka, Yoshimi
Hagiwara, kazuhisa
Hirai, Hideaki
Morohashi, Satoko
Kijima, Hiroshi
Yamamoto, Hayato
Tobisawa, Yuki
Yoneyama, Tohru
Yoneyama, Takahiro
Hashimoto, Yasuhiro
Koie, Takuya
Ohyama, Chikara
|
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Pathol & Biosci, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Pathol & Biosci, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Adv Transplant & Regenerat Med, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background and Objective: A quantitative tumor response evaluation to molecular-targeting agents in advanced renal cell carcinoma (RCC) is debatable. We aimed to evaluate the relationship between radiologic tumor response and pathological response in patients with advanced RCC who underwent presurgical therapy.
Results: Of 34 patients, 31 underwent scheduled radical nephrectomy. Presurgical therapy agents included axitinib (n = 26), everolimus (n = 3), sunitinib (n = 1), and axitinib followed by temsirolimus (n = 1). The major presurgical treatment-related adverse event was grade 2 or 3 hypertension (44%). The median radiologic tumor response by RECIST, Choi, and CMER were -19%, -24%, and -49%, respectively. Among the radiologic tumor response tests, CMER showed a higher association with tumor necrosis in surgical specimens than others. Ki67/MIB1 status was significantly decreased in surgical specimens than in biopsy specimens. The magnitude of the slope of the regression line associated with the tumor necrosis percentage was greater in CMER than in Choi and RECIST.
Materials and Methods: Between March 2012 and December 2016, we prospectively enrolled 34 locally advanced and/or metastatic RCC who underwent presurgical molecular-targeting therapy followed by radical nephrectomy. Primary endpoint was comparison of radiologic tumor response among Response Evaluation Criteria in Solid Tumors (RECIST), Choi, and contrast media enhancement reduction (CMER). Secondary endpoint included pathological downstaging, treatment related adverse events, postoperative complications, Ki67/MIB1 status, and tumor necrosis.
Conclusions: CMER may predict tumor response after presurgical moleculartargeting therapy. Larger prospective studies are needed to develop an optimal tumor response evaluation for molecular-targeting therapy. |
| 書誌情報 |
ONCOTARGET
巻 8,
号 30,
p. 49749-49756,
発行日 2017-07-25
|
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1949-2553 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.18632/oncotarget.17930 |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 資源タイプ |
|
|
値 |
Article |
oncotarget-49749 (12.3 MB)
